IP Library › Granted Patent US 10,077,317
Granted Patent B2
US 10,077,317 · App. 14/280,017 · Granted Sep 18, 2018

Antibodies for epidermal growth factor receptor 3 (HER3)

Inventors: Andrew Paul Garner (Cambridge, MA); Elizabeth Anne Reisinger Sprague (Cambridge, MA); Seth Alexander Ettenberg (Cambridge, MA); Christian Kunz (Munich, DE); Nicole Haubst (Munich, DE); Winfried Elis (Munchen-Pasing, DE)
Assignee: Novartis AG
C07K16/32A61K39/39558A61K45/06C07K16/30C07K16/303C07K16/3015C07K16/3023C07K16/3038C07K16/3046C07K16/3053C07K16/3061C07K16/3069A61K2039/505C07K2317/21C07K2317/24C07K2317/33C07K2317/34C07K2317/522C07K2317/524C07K2317/526C07K2317/55C07K2317/56C07K2317/565C07K2317/567C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,077,317
App. No.
14/280,017
Granted
Sep 18, 2018
Kind
B2
Abstract

The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.

Claims (7)

1. An isolated monoclonal antibody or fragment thereof that specifically binds to a HER3 receptor, comprising a combination of human heavy and light germline framework regions, wherein the monoclonal antibody or fragment thereof comprises:

a heavy chain variable region (VH) that comprises:

SEQ ID NO: 409; and

a light chain variable region (VL) that comprises:

SEQ ID NO: 444.

2. The isolated monoclonal antibody or fragment thereof of claim 1 , wherein the monoclonal antibody or fragment thereof comprises a FW4 (JH) sequence selected from the group consisting of SEQ ID NO: 465, SEQ ID NO: 466, SEQ ID NO: 462, SEQ ID NO: 464, SEQ ID NO: 467, and SEQ ID NO: 463.

3. The isolated monoclonal antibody or fragment thereof of claim 1 , wherein the monoclonal antibody or fragment thereof comprises a FW4 (JK) sequence selected from the group consisting of SEQ ID NO: 470, SEQ ID NO: 471, SEQ ID NO: 468, SEQ ID NO: 469, and SEQ ID NO: 472.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2018
From: ETTENBERG, SETH; GARNER, ANDREW PAUL; REISINGER SPRAGUE, ELIZABETH ANNE
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
Reel/Frame 045637/0883 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2018
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.
To: NOVARTIS AG
Reel/Frame 045637/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2018
From: ELIS, WINFRIED; HAUBST, NICOLE; KUNZ, CHRISTIAN CARSTEN SILVESTER
To: MORPHOSYS AG
Reel/Frame 045637/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2018
From: MORPHOSYS AG
To: NOVARTIS AG
Reel/Frame 045638/0004 →
Continuity (3)
Continuation 13214413 · Aug 22, 2011
Provisional Application 61375408 · Aug 20, 2010
Related Publication 20170166653A1 · Jun 15, 2017